References
- 1. Mortimer AM - Update on the management of symptoms in schizophrenia: focus on amisulpride. Neuropsychiatr Dis Treat. 2009;5:267-77
- 2. Gonçalves P, Araújo JR, Martel F - Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Eur. Neuropsychopharmacol. 2015 Jan;25(1):1-1610.1016/j.euroneuro.2014.11.008
- 3. Monreal Ortiz D, Chesa Vela E, Surribas Leza C, Franquelo C - P.3.c.0671. The effects of amisulpride on weight and metabolic parameters in psychotic patients with surcharge weight, European Neuropsychopharmacology, 2009, 19 (9): S548-S54910.1016/S0924-977X(09)70874-0
- 4. Patsch JR, Ebenbichler CF - Metabolic side effects of antipsychotic medication. International Journal Clinical Practice 2007, 61, 8, 1356–137010.1111/j.1742-1241.2007.01416.x17627711
- 5. Correll CU, Lencz T, Malhotra AK - Antipsychotic drugs and obesity. Trends Mol Med. 2011 Feb;17(2):97-107.10.1016/j.molmed.2010.10.010305358521185230
- 6. Reynolds GP, Kirk SL - Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacol Ther. 2010 Jan;125(1):169-7910.1016/j.pharmthera.2009.10.01019931306
- 7. Di Giovanni G, Di Mascio M, Di Matteo V et al - Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons. J Pharmacol Exp Ther. 1998 Oct;287(1):51-57.
- 8. Natesan S, Reckless GE, Barlow KBL - Amisulpride-the ‘atypical’ atypical antipsychotic-Comparison to haloperidol, risperidone and olanzapine. Schizophrenia Research, 2008, 105:224-23510.1016/j.schres.2008.07.00518710798
- 9. Vanelle JM, Douki S - A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry.2006;21(8):523-3010.1016/j.eurpsy.2006.09.00317113759
- 10. Roix JJ, DeCrescenzo GA, Cheung PH et al - Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion. Diabetes Obes Metab. 2012 Apr;14(4):329-3410.1111/j.1463-1326.2011.01529.x22059694
- 11. Lin CC, Bai YM, Wang YC et al - Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics. J Clin Psychopharmacol. 2009 Dec;29(6):529-3610.1097/JCP.0b013e3181bf613e19910716
- 12. Peuskens J. De Hert M, Mortimer A - SOLIANOL Study Group. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol. 2007 May;22(3):145-5210.1097/YIC.0b013e3280148c2917414740
- 13. Schoemaker H, Claustre Y, Fage D et al - Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with bothpresynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997; 280(1):83-97
- 14. Donahue TJ, Hillhouse TM, Webster KA et al - (S)-amisulpride as a discriminative stimulus in C57BL/6 mice and its comparison to the stimulus effects of typical and atypical antipsychotics. Eur J Pharmacol. 2014 Jul 5;734:15-2210.1016/j.ejphar.2014.03.04724726559
- 15. Perrault G, Depoortere R, Morel E et al - Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptorantagonist activity and limbic selectivity. J Pharmacol Exp Ther. 1997;280(1):73-82
- 16. Krebs S, Dormann H, Muth-Selbach U et al - Risperidone-induced cholestatic hepatitis. Eur J Gastroenterol Hepatol. 2001 Jan;13(1):67-910.1097/00042737-200101000-0001311204814
- 17. López-Torres E, Süveges A, Peñas-LLedó EM et al - Liver enzyme abnormalities during antipsychotic treatment: a case report of risperidone-associated hepatotoxicity. Drug Metabol Drug Interact. 2014;29(2):123-6
- 18. Manceaux P, Constant E, Zdanowicz N et al - Management of marked liver enzyme increase during olanzapine treatment: a case report and review of the literature. Psychiatr Danub. 2011 Sep;23 Suppl 1:S15-7.